

Human LILRA3/CD85e Protein

Cat. No. LIL-HM4A3

Description

Source	Recombinant Human LILRA3/CD85e Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gly24-Glu439.
Accession	Q8N6C8
Molecular Weight	The protein has a predicted MW of 47.9 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Human LILRA3, also known as Leukocyte Ig-like receptor 4 (LIR-4), CD85 antigen-like family member E, Immunoglobulin-like transcript 6 (ILT-6) and monocyte inhibitory receptor HM43/HM31, is a 70 kD Ig superfamily member that belongs to the leukocyte receptor complex/cluster. Mature LILRA3 is 416 amino acids (aa) in length and contains four C2-type Ig-like domains. Unlike other LILR family members, LILRA3 is actively secreted. LILRA3 acts as soluble receptor for class I MHC antigens. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes.

Assay Data

Tris-Bis PAGE



Human LILRA3 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.